Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Abstract

New improved vaccines are needed for control of both bovine and human tuberculosis. Tuberculosis protein vaccines have advantages with regard to safety and ease of manufacture, but efficacy against tuberculosis has been difficult to achieve. Protective cellular immune responses can be preferentially induced when antigens are displayed on small particles. In this study, Escherichia coli and Lactococcus lactis were engineered to produce spherical polyhydroxybutyrate (PHB) inclusions which displayed a fusion protein of Mycobacterium tuberculosis, antigen 85A (Ag85A)-early secreted antigenic target 6-kDa protein (ESAT-6). L. lactis was chosen as a possible production host due its extensive use in the food industry and reduced risk of lipopolysaccharide contamination. Mice were vaccinated with PHB bead vaccines with or without displaying Ag85A-ESAT-6, recombinant Ag85A-ESAT-6, or M. bovis BCG. Separate groups of mice were used to measure immune responses and assess protection against an aerosol M. bovis challenge. Increased amounts of antigen-specific gamma interferon, interleukin-17A (IL-17A), IL-6, and tumor necrosis factor alpha were produced from splenocytes postvaccination, but no or minimal IL-4, IL-5, or IL-10 was produced, indicating Th1- and Th17-biased T cell responses. Decreased lung bacterial counts and less extensive foci of inflammation were observed in lungs of mice receiving BCG or PHB bead vaccines displaying Ag85A-ESAT-6 produced in either E. coli or L. lactis compared to those observed in the lungs of phosphate-buffered saline-treated control mice. No differences between those receiving wild-type PHB beads and those receiving recombinant Ag85A-ESAT-6 were observed. This versatile particulate vaccine delivery system incorporates a relatively simple production process using safe bacteria, and the results show that it is an effective delivery system for a tuberculosis protein vaccine.

• Authors: Natalie A Parlane, Katrin Grage, Jun Mifune, Randall J Basaraba, D Neil Wedlock, Bernd H A Rehm, Bryce M Buddle
• Journal: Clinical and vaccine immunology : CVI (Clin Vaccine Immunol) Vol. 19 Issue 1 Pg. 37-44 (Jan 2012) ISSN: 1556-679X [Electronic] United States
• PMID: 22072720 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Bacterial
• Bacterial Proteins
• Cytokines
• Drug Carriers
• ESAT-6 protein, Mycobacterium tuberculosis
• Hydroxybutyrates
• PHB protein, human
• Polyesters
• Prohibitins
• Recombinant Fusion Proteins
• Tuberculosis Vaccines
• poly-beta-hydroxybutyrate
• Acyltransferases
• antigen 85A, Mycobacterium tuberculosis

Topics

• Acyltransferases (genetics, immunology, metabolism)
• Animals
• Antigens, Bacterial (genetics, immunology, metabolism)
• Bacterial Load
• Bacterial Proteins (genetics, immunology, metabolism)
• Cytokines (metabolism)
• Disease Models, Animal
• Drug Carriers (administration & dosage, metabolism)
• Escherichia coli (genetics, metabolism)
• Female
• Hydroxybutyrates (administration & dosage, metabolism)
• Immunity, Cellular
• Lactococcus lactis (genetics, metabolism)
• Leukocytes, Mononuclear (immunology)
• Lung (microbiology)
• Mice
• Mice, Inbred C57BL
• Microspheres
• Polyesters (administration & dosage, metabolism)
• Prohibitins
• Recombinant Fusion Proteins (genetics, immunology, metabolism)
• Spleen (immunology)
• Tuberculosis (prevention & control)
• Tuberculosis Vaccines (administration & dosage, genetics, immunology, metabolism)